TGFB1 and chronic myelogenous leukemia, BCR-ABL1 positive: Conversely, the downregulated DEGs were prominently enriched in PD-L1 expression and the PD-1 checkpoint pathway in cancer, pathways in cancer, TGF-β, estrogen-signaling pathways and so on (Figure 8D), which were all targets against CML.